338 related articles for article (PubMed ID: 11217868)
1. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
Moyle G
Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
[TBL] [Abstract][Full Text] [Related]
2. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
3. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG
AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163
[TBL] [Abstract][Full Text] [Related]
4. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Casado JL; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
AIDS; 2000 Jan; 14(2):F1-7. PubMed ID: 10708276
[TBL] [Abstract][Full Text] [Related]
5. NNRTIs: a neglected class.
Cadman J
GMHC Treat Issues; 1998 Sep; 12(9):6-10. PubMed ID: 11365807
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
Torre D; Tambini R; Speranza F
HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
[TBL] [Abstract][Full Text] [Related]
7. Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection.
Moyle GJ
Curr Opin Infect Dis; 2000 Feb; 13(1):19-25. PubMed ID: 11964768
[TBL] [Abstract][Full Text] [Related]
8. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA
HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065
[TBL] [Abstract][Full Text] [Related]
9. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
Zhang Z; Hamatake R; Hong Z
Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz.
Adkins JC; Noble S
Drugs; 1998 Dec; 56(6):1055-64; discussion 1065-6. PubMed ID: 9878993
[TBL] [Abstract][Full Text] [Related]
13. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
[TBL] [Abstract][Full Text] [Related]
14. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
15. A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.
Manfredi R; Calza L; Chiodo F
J Antimicrob Chemother; 2002 May; 49(5):723-9. PubMed ID: 12003964
[TBL] [Abstract][Full Text] [Related]
16. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV.
Sheran M
HIV Clin Trials; 2005; 6(3):158-68. PubMed ID: 16192249
[TBL] [Abstract][Full Text] [Related]
17. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Penazzato M; Giaquinto C
Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and durability of nevirapine in antiretroviral drug näive patients.
Lange JM
J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S40-52. PubMed ID: 14562857
[TBL] [Abstract][Full Text] [Related]
19. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
20. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]